Evidence map›Paper›PMID 38520086›Full record

ReviewESC heart failure2024

Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement.

Ovidiu Chioncel, Jelena Čelutkienė, Jan Bělohlávek, Ginta Kamzola, Mitja Lainscak, Béla Merkely, Davor Miličić, Jadwiga Nessler, Arsen D Ristić, Lidia Sawiełajc and 5 more

Abstract readReview
In one paragraph

Review in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Gut microbiota's role in heart failure.Heart failure reviews · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. High-intensity care for GDMT titration.Heart failure reviews · 2024
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ovidiu ChioncelEmergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu', Bucharest, Romania.
Jelena ČelutkienėClinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University/State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
Jan BělohlávekSecond Department of Medicine, Cardiovascular Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czechia.
Ginta KamzolaLatvian Centre of Cardiology, Pauls Stradiņš Clinical University Hospital, Riga, Latvia.
Mitja LainscakDivision of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia.
Béla MerkelyHeart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Davor MiličićDepartment of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
Jadwiga NesslerDepartment of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland.
Arsen D RistićDepartment of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia.
Lidia SawiełajcAstraZeneca, Warsaw, Poland.
Izabella UchmanowiczDepartment of Nursing and Obstetrics, Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland.
Tiina UuetoaConfido Healthcare Centre, Tallinn, Estonia.
Eva TurgonyiAstraZeneca GCC, Dubai, United Arab Emirates.
Yoto YotovFirst Department of Internal Diseases, Faculty of Medicine, Medical University of Varna, Varna, Bulgaria.
Piotr PonikowskiInstitute of Heart Diseases, University Hospital, Wrocław, Poland.

Funding

AstraZeneca
6 · The paper itself

Abstract

Despite improvements over recent years, morbidity and mortality associated with heart failure (HF) are higher in countries in the Central and Eastern Europe and Baltic region than in Western Europe. With the goal of improving the standard of HF care and patient outcomes in the Central and Eastern Europe and Baltic region, this review aimed to identify the main barriers to optimal HF care and potential areas for improvement. This information was used to suggest methods to improve HF management and decrease the burden of HF in the region that can be implemented at the national and regional levels. We performed a literature search to collect information about HF epidemiology in 11 countries in the region (Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, and Slovenia). The prevalence of HF in the region was 1.6-4.7%, and incidence was 3.1-6.0 per 1000 person-years. Owing to the scarcity of published data on HF management in these countries, we also collected insights on local HF care and management practices via two surveys of 11 HF experts representing the 11 countries. Based on the combined results of the literature review and surveys, we created national HF care and management profiles for each country and developed a common patient pathway for HF for the region. We identified five main barriers to optimal HF care: (i) lack of epidemiological data, (ii) low awareness of HF, (iii) lack of national HF strategies, (iv) infrastructure and system gaps, and (v) poor access to novel HF treatments. To overcome these barriers, we propose the following routes to improvement: (i) establish regional and national prospective HF registries for the systematic collection of epidemiological data; (ii) establish education campaigns for the public, patients, caregivers, and healthcare professionals; (iii) establish formal HF strategies to set clear and measurable policy goals and support budget planning; (iv) improve access to quality-of-care centres, multidisciplinary care teams, diagnostic tests, and telemedicine/telemonitoring; and (v) establish national treatment monitoring programmes to develop policies that ensure that adequate proportions of healthcare budgets are reserved for novel therapies. These routes to improvement represent a first step towards improving outcomes in patients with HF in the Central and Eastern Europe and Baltic region by decreasing disparities in HF care within the region and between the region and Western Europe.

Indexed as

Heart FailureBaltic StatesDisease ManagementEuropeEurope, EasternHumansMorbidityPrevalenceQuality ImprovementCentral and Eastern Europe and Baltic regionHeart failure managementHeart failure nursingMultidisciplinary carePatient pathwayRegistries

Identifiers

PMID38520086
PMCPMC11287314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.